Indications for use:
For the treatment of chronic, recurrent conjunctivitis resulting from autoimmune disease of the eye. Indicated for the therapeutic treatment of Keratoconjunctivitis sicca (KCS, ‘dry eye’) and chronic superficial keratitis (‘pannus’) in the dog.
May be used to augment topical corticosteroids or as a substitute for corticosteroids when these are contraindicated by corneal ulceration.
Do not use where fungal or viral infection of the eye is suspected.
Special warnings for each target species:
Clinical experience has shown than 90% of dogs affected with KCS will require life-long therapy. However, if therapy is maintained, the prognosis is good providing that regular clinical assessment is conducted.
Similarly, chronic superficial keratitis may require continuous therapy although, as the condition is exacerbated by ultraviolet light, requirement for treatment may be suspended or reduced at certain times of the year.
In the treatment of KCS, it is important that continuous treatment is maintained. Studies have shown that stimulation of tear production ceases within 24 hours of withdrawing treatment.
Increase in tear production is expected within 10 days but may not be maximal until 6 weeks from commencement of treatment.
Special precautions for use:
For external topical use only.
Care should be taken to avoid contamination of the contents during use.
Replace cap between applications.